Cargando…

Corrigendum to “Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis”

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445523/ https://www.ncbi.nlm.nih.gov/pubmed/34729146 http://dx.doi.org/10.1177/20406223211046076

Ejemplares similares

Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis
por: Zrzavy, Tobias, et al.
Publicado: (2021)

Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines – in vitro studies [Corrigendum]
Publicado: (2015)

Corrigendum to Serum hepcidin levels in multiple sclerosis
Publicado: (2020)

Corrigendum to ’To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection’[Multiple sclerosis and related disorders vol. 65 (2022) 104014]
por: Stastna, Dominika, et al.
Publicado: (2023)

Corrigendum to miRNAs in Microglia: Important Players in Multiple Sclerosis Pathology
Publicado: (2022)

Corrigendum: Brain network correlates of epilepsy occurrence in multiple sclerosis and neuroinflammation
Publicado: (2023)

Corrigendum: Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis
Publicado: (2021)

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
por: Rezaee, Mehdi, et al.
Publicado: (2022)

CORRIGENDUM to Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
Publicado: (2023)

NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab [Corrigendum]
Publicado: (2013)

Corrigendum to “A Longitudinal Examination of the Hopelessness Theory of Depression in People Who Have Multiple Sclerosis”
por: Kneebone, I. I., et al.
Publicado: (2020)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
Publicado: (2014)

Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study
por: Tabrizi, Nasim, et al.
Publicado: (2012)

Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant [Corrigendum]
Publicado: (2018)

Multimodal intervention improves fatigue and quality of life in subjects with progressive multiple sclerosis: a pilot study [Corrigendum]
Publicado: (2015)

Corrigendum to “Relapsed multiple myeloma manifesting as extramedullary plasmacytoma of the breast: Imaging findings” [Radiology Case Reports 14 (2019) 584–587]
por: Urano, Misugi, et al.
Publicado: (2020)

Expression analysis of protein inhibitor of activated STAT (PIAS) genes in IFNβ-treated multiple sclerosis patients [Corrigendum]
Publicado: (2019)

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]
Publicado: (2017)

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
por: Boremalm, Malin, et al.
Publicado: (2021)

Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis
por: Shima, Ayano, et al.
Publicado: (2019)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
por: Hernández-Preciado, Martha Rocio, et al.
Publicado: (2022)

Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study
por: Buttmann, Mathias, et al.
Publicado: (2016)

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]
Publicado: (2014)

Corrigendum to “Advances of Techniques in Deep Regional Blocks”
por: Lin, Jui-An, et al.
Publicado: (2018)

Corrigendum to “Relapse of prostate cancer from the viewpoint of total gland volume kinetics theory” by Hiroki Watanabe
por: Watanabe, Hiroki
Publicado: (2016)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum]
Publicado: (2020)

Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review
por: Castillo-Trivino, Tamara, et al.
Publicado: (2013)

Corrigendum: Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective
Publicado: (2023)

The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution [Corrigendum]
Publicado: (2020)

Smartphone Health Assessment for Relapse Prevention (SHARP): a digital solution toward global mental health – CORRIGENDUM
por: Rodriguez-Villa, Elena, et al.
Publicado: (2021)

Corrigendum to: Advances in plant reproduction: from gametes to seeds
por: Pereira, Ana Marta, et al.
Publicado: (2020)

Corrigendum: A first step toward understanding patient safety
por: Kim, Kyoung Ok
Publicado: (2017)

Raw milk producers with high levels of hygiene and safety – CORRIGENDUM
por: Berge, A. C., et al.
Publicado: (2020)

Corrigendum to “Safety of integrated mass drug administration of azithromycin, albendazole and ivermectin versus standard treatment regimens: a cluster-randomised trial in Ethiopia”
por: McPherson, Scott, et al.
Publicado: (2023)

Corrigendum to “The Effectiveness, Tolerability, and Safety of Different 1-Day Bowel Preparation Regimens for Pediatric Colonoscopy”
por: Szaflarska-Poplawska, Anna, et al.
Publicado: (2020)

A Case of Marburg's Variant of Multiple Sclerosis Successfully Treated with IVIg and Mitoxantrone
por: Manuel, Adarsh, et al.
Publicado: (2021)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Siegel, D S, et al.
Publicado: (2014)

Cardiotoxicity of Mitoxantrone Treatment in a German Cohort of 639 Multiple Sclerosis Patients
por: Fleischer, Vinzenz, et al.
Publicado: (2014)

Corrigendum to “Comparative Sensitivity Analysis of Muscle Activation Dynamics”
por: Rockenfeller, Robert, et al.
Publicado: (2017)

Comparative Analysis of Commercial Colloidal Silver Products [Corrigendum]
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pq2q0lmmfquv1j1tbb6r9am87j